218 related articles for article (PubMed ID: 30213731)
1. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.
Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS
Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
3. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
4. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
[No Abstract] [Full Text] [Related]
5. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.
Michalon A; Hagenbuch A; Huy C; Varela E; Combaluzier B; Damy T; Suhr OB; Saraiva MJ; Hock C; Nitsch RM; Jan Grimm
Nat Commun; 2021 May; 12(1):3142. PubMed ID: 34035264
[TBL] [Abstract][Full Text] [Related]
6. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
7. Inotersen treatment for ATTR amyloidosis.
Benson MD
Amyloid; 2019; 26(sup1):27-28. PubMed ID: 31343345
[No Abstract] [Full Text] [Related]
8. Myopathic phenotype of familial amyloid polyneuropathy with a rare transthyretin variant: ATTR Ala45Asp.
Misumi Y; Doki T; Ueda M; Obayashi K; Tasaki M; Tamura A; Ando Y
Amyloid; 2014 Sep; 21(3):216-7. PubMed ID: 24953234
[No Abstract] [Full Text] [Related]
9. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.
Wixner J; Westermark P; Ihse E; Pilebro B; Lundgren HE; Anan I
Amyloid; 2019; 26(sup1):39-40. PubMed ID: 31343354
[No Abstract] [Full Text] [Related]
10. Transthyretin amyloidosis in patients with undifferentiated heart failure.
Chang IC; Scott CG; Dispenzieri A; AbouEzzeddine O; Lin G; Grogan M
Amyloid; 2019; 26(sup1):33-34. PubMed ID: 31343280
[No Abstract] [Full Text] [Related]
11. Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
Nakano Y; Tadokoro K; Ohta Y; Sato K; Takemoto M; Hishikawa N; Yamashita T; Yamashita T; Ando Y; Abe K
J Neurol Sci; 2018 Jul; 390():22-25. PubMed ID: 29801893
[No Abstract] [Full Text] [Related]
12. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin amyloidosis: a little history of hereditary amyloidosis.
Benson MD
Amyloid; 2017 Mar; 24(sup1):76-77. PubMed ID: 28434305
[No Abstract] [Full Text] [Related]
14. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model.
Teixeira C; Costelha S; Martins HS; Teixeira A; Saraiva MJ
Amyloid; 2017 Mar; 24(sup1):80. PubMed ID: 28434372
[No Abstract] [Full Text] [Related]
16. Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous.
Bezerra F; Simões CJV; Beirão JM; Saraiva MJ; Brito RMM; Almeida MR
Amyloid; 2019; 26(sup1):73-74. PubMed ID: 31343304
[No Abstract] [Full Text] [Related]
17. Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.
Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
Amyloid; 2019; 26(sup1):26. PubMed ID: 31343346
[No Abstract] [Full Text] [Related]
18. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
19. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).
Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM
Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724
[No Abstract] [Full Text] [Related]
20. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Castro J; Costa J; de Castro I; Conceição I
Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
